News | June 08, 2022
ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Subscribe To Our Newsletter & Stay Updated
